As pharma companies try to get more compounded GLP-1 users on branded versions of the drugs, they’re embracing certain ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

GSK agreed to buy an experimental medicine from a Cambridge biotech for as much as $2 billion to shore up its drug pipeline and muscle into the promising field of liver therapies. The treatment ...

GSK exited Kenya in 2023 as part of its restructuring and now supplies its medicines and vaccines through a third-party distributor. Be part of an exclusive group of enthusiasts! Get fresh content ...

Explore how GSK's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the ...

Bearish flow noted in GSK (GSK) Pharma with 2,330 puts trading, or 1.1x expected. Most active are 2/14 weekly 36 puts and 2/28 weekly 36 puts, with total volume in those strikes near 1,600 contracts.

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

Bearish flow noted in GSK (GSK) Pharma with 14,964 puts trading, or 17x expected. Most active are 11/1 weekly 37 puts and 11/1 weekly 38.5 calls, with total volume in those strikes near 19,700 ...

GSK will pay up to $2.2 billion to resolve 93% of U.S. Zantac cases. GSK expects to recognize a £1.8 billion ($2.3 billion) charge in Q3 2024 related to these settlements. Rebound or breakdown ...

GSK stock has a long track record of lagging behind the broader markets. Under CEO Emma Walmsley, the drugmaker has made significant strides toward improving its core-value proposition to ...

GSK and Ochre Bio will work together in a $37.5 million partnership to pinpoint the drivers of liver disease. The new partnership, announced Wednesday morning, will see GSK access Ochre’s ...